Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
febuxostat
- Development stage
- Approved
- Lead developer
- Teijin Pharma
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Febuxostat is a non-purine xanthine oxidase inhibitor used for the long-term management of chronic hyperuricemia in adults with gout who have an inadequate response to or intolerance of allopurinol. It works by selectively and non-competitively inhibiting xanthine oxidase, the enzyme responsible for converting hypoxanthine and xanthine into uric acid, thereby reducing serum uric acid levels. Febuxostat is taken orally and is generally reserved for patients unable to use allopurinol due to efficacy or tolerability issues. The drug was first approved in Europe in 2008 and subsequently by the FDA in 2009. Clinical trials have shown an increased risk of cardiovascular death compared to allopurinol, so its use is typically limited to those who cannot take other therapies[1][3][5][7].
- Brand names
- UloricAdenuric
- Other names
- febuxostat SR
02
Targets
ABCG2 (Breast cancer resistance protein)XO (Xanthine Oxidoreductase)
Beyond the preview
Go deeper on febuxostat.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on febuxostat.